These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36972942)

  • 21. Heterozygous familial hypercholesterolemia in children: low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein-lipid concentrations.
    Torres AL; Moorjani S; Vohl MC; Gagné C; Lamarche B; Brun LD; Lupien PJ; Després JP
    Atherosclerosis; 1996 Sep; 126(1):163-71. PubMed ID: 8879444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LDLR c.89_92dup: a novel frameshift variation in familial hypercholesterolemia.
    Deng J; Zhang J; Meng S; Ding N; Hao Y; Zeng H; Lin J
    Lipids Health Dis; 2024 Jun; 23(1):182. PubMed ID: 38867270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease.
    Al-Allaf FA; Athar M; Abduljaleel Z; Taher MM; Khan W; Ba-Hammam FA; Abalkhail H; Alashwal A
    Gene; 2015 Jul; 565(1):76-84. PubMed ID: 25839937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Compound heterozygous familial hypercholesterolemia in a Chinese boy with a de novo and transmitted low-density lipoprotein receptor mutation.
    Ma Y; Gong Y; Garg A; Zhou H
    J Clin Lipidol; 2018; 12(1):230-235.e6. PubMed ID: 29233637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a novel LDLR disease-causing variant using capture-based next-generation sequencing screening of familial hypercholesterolemia patients in Taiwan.
    Hsiung YC; Lin PC; Chen CS; Tung YC; Yang WS; Chen PL; Su TC
    Atherosclerosis; 2018 Oct; 277():440-447. PubMed ID: 30270083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A de novo mutation of the LDL receptor gene as the cause of familial hypercholesterolemia identified using whole exome sequencing.
    Tada H; Hosomichi K; Okada H; Kawashiri MA; Nohara A; Inazu A; Tomizawa S; Tajima A; Mabuchi H; Hayashi K
    Clin Chim Acta; 2016 Jan; 453():194-6. PubMed ID: 26721317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic analysis and management of a familial hypercholesterolemia pedigree with polygenic variants: Case report.
    Han Y; Zhang L; Tao H; Wu J; Zhai J
    Medicine (Baltimore); 2023 Aug; 102(32):e34534. PubMed ID: 37565868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of New Genetic Determinants in Pediatric Patients with Familial Hypercholesterolemia Using a Custom NGS Panel.
    Rutkowska L; Sałacińska K; Salachna D; Matusik P; Pinkier I; Kępczyński Ł; Piotrowicz M; Starostecka E; Lewiński A; Gach A
    Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spectrum of mutations in index patients with familial hypercholesterolemia in Singapore: Single center study.
    Pek SLT; Dissanayake S; Fong JCW; Lin MX; Chan EZL; Tang JI; Lee CW; Ong HY; Sum CF; Lim SC; Tavintharan S
    Atherosclerosis; 2018 Feb; 269():106-116. PubMed ID: 29353225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
    Jensen HK
    Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperlipidemia patients carrying LDLR splicing mutation c.1187-2A>G respond favorably to rosuvastatin and PCSK9 inhibitor evolocumab.
    Zhang X; Liu Q; Zhang H; Tan C; Zhu Q; Chen S; Du Y; Yang H; Li Q; Xu C; Wu C; Wang QK
    Mol Genet Genomics; 2022 May; 297(3):833-841. PubMed ID: 35441343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of New Copy Number Variation and the Evaluation of a CNV Detection Tool for NGS Panel Data in Polish Familial Hypercholesterolemia Patients.
    Rutkowska L; Pinkier I; Sałacińska K; Kępczyński Ł; Salachna D; Lewek J; Banach M; Matusik P; Starostecka E; Lewiński A; Płoski R; Stawiński P; Gach A
    Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R).
    Schaefer JR; Kurt B; Sattler A; Klaus G; Soufi M
    Clin Res Cardiol Suppl; 2012 Jun; 7(Suppl 1):2-6. PubMed ID: 22528129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction between the LDL-receptor gene bearing a novel mutation and a variant in the apolipoprotein A-II promoter: molecular study in a 1135-member familial hypercholesterolemia kindred.
    Takada D; Emi M; Ezura Y; Nobe Y; Kawamura K; Iino Y; Katayama Y; Xin Y; Wu LL; Larringa-Shum S; Stephenson SH; Hunt SC; Hopkins PN
    J Hum Genet; 2002; 47(12):656-64. PubMed ID: 12522687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rare intracranial cholesterol deposition and a homozygous mutation of LDLR in a familial hypercholesterolemia patient.
    Li H; Zhang Y; Wei X; Peng Y; Yang P; Tan H; Chen C; Pan Q; Liang D; Wu L
    Gene; 2015 Sep; 569(2):313-7. PubMed ID: 25936346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of clinical diagnosis criteria of familial ligand defective apoB 100 and lipoprotein phenotype comparison between LDL receptor gene mutations affecting ligand-binding domain and the R3500Q mutation of the apoB gene in patients from a South European population.
    Ejarque I; Real JT; Martinez-Hervas S; Chaves FJ; Blesa S; Garcia-Garcia AB; Millan E; Ascaso JF; Carmena R
    Transl Res; 2008 Mar; 151(3):162-7. PubMed ID: 18279815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients.
    Hori M; Ohta N; Takahashi A; Masuda H; Isoda R; Yamamoto S; Son C; Ogura M; Hosoda K; Miyamoto Y; Harada-Shiba M
    Atherosclerosis; 2019 Oct; 289():101-108. PubMed ID: 31491741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
    Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
    Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterozygous familial hypercholesterolaemia in a pair of identical twins: a case report and updated review.
    Mohd Nor NS; Al-Khateeb AM; Chua YA; Mohd Kasim NA; Mohd Nawawi H
    BMC Pediatr; 2019 Apr; 19(1):106. PubMed ID: 30975109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.
    Ohta N; Hori M; Takahashi A; Ogura M; Makino H; Tamanaha T; Fujiyama H; Miyamoto Y; Harada-Shiba M
    J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.